Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$0.52 -8.7%	$0.50	$0.40 ▼ $3.02	$30.30M	1.13	520,729 shs	415,913 shs
ANVS Annovis Bio	$2.51 -8.1%	$2.64	$1.11 ▼ $10.54	$53.20M	1.51	324,064 shs	349,630 shs
CGC Canopy Growth	$1.05 +1.9%	$1.29	$0.77 ▼ $7.21	$211.30M	0.68	9.52 million shs	6.96 million shs
LRMR Larimar Therapeutics	$3.44 -0.6%	$2.99	$1.61 ▼ $9.50	$221.54M	0.93	1.06 million shs	1.16 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-8.70%	-1.54%	+16.43%	-2.78%	-89.21%
ANVS Annovis Bio	-7.55%	-13.89%	+5.46%	+55.42%	-73.10%
CGC Canopy Growth	+1.94%	-7.89%	-11.76%	-21.05%	-86.18%
LRMR Larimar Therapeutics	-0.58%	-11.34%	+10.61%	+15.82%	-59.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.2354 of 5 stars	3.4	3.0	1.1	4.2	1.3
ANVS Annovis Bio	1.985 of 5 stars	3.5	1.0	2.0	1.7	0.6
CGC Canopy Growth	0.6116 of 5 stars	0.0	2.0	3.2	0.0	1.3
LRMR Larimar Therapeutics	2.246 of 5 stars	3.6	2.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	536.94% Upside
ANVS Annovis Bio	3.00	Buy	$18.00	617.13% Upside
CGC Canopy Growth	1.00	Sell	N/A	N/A
LRMR Larimar Therapeutics	3.11	Buy	$18.50	437.79% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, LRMR, and CGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
5/30/2025	CGC Canopy Growth	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight
5/21/2025	ALXO ALX Oncology	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1.20 ➝ $1.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/9/2025	ALXO ALX Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$2.14 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CGC Canopy Growth	$225.65M	0.95	N/A	N/A	$1.90 per share	0.55
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.47	N/A	N/A	N/A	N/A	-104.43%	-77.74%	8/14/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
CGC Canopy Growth	-$429.86M	-$4.04	N/A	N/A	N/A	-195.76%	-88.54%	-40.78%	8/8/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)

Latest ANVS, ALXO, LRMR, and CGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ALXO ALX Oncology	-$0.46	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	ANVS Annovis Bio	-$0.36	N/A	N/A	N/A	N/A	N/A
8/8/2025	Q1 2026	CGC Canopy Growth	-$0.10	N/A	N/A	N/A	$64.98 million	N/A
8/6/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
5/30/2025	Q4 2025	CGC Canopy Growth	-$0.28	-$0.94	-$0.66	-$1.00	$71.84 million	$45.30 million
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/8/2025	Q1 2025	ALXO ALX Oncology	-$0.47	-$0.58	-$0.11	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.09	5.47	5.47
ANVS Annovis Bio	N/A	10.68	10.68
CGC Canopy Growth	0.62	3.12	2.10
LRMR Larimar Therapeutics	N/A	7.48	7.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
CGC Canopy Growth	3.33%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
ANVS Annovis Bio	20.80%
CGC Canopy Growth	1.30%
LRMR Larimar Therapeutics	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.40 million	42.18 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
CGC Canopy Growth	3,150	205.15 million	202.48 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable

ANVS, ALXO, LRMR, and CGC Headlines

Recent News About These Companies

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

July 31 at 4:15 PM | globenewswire.com

Larimar Therapeutics shares drop following $60 million public offering

July 30 at 1:24 PM | msn.com

Larimar Therapeutics (LRMR) Expected to Announce Quarterly Earnings on Wednesday

July 30 at 3:47 AM | marketbeat.com

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock

July 29, 2025 | quiverquant.comQ

Larimar Therapeutics Announces Proposed Underwritten Public Offering

July 29, 2025 | globenewswire.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.50 Consensus PT from Brokerages

July 29, 2025 | americanbankingnews.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Buy" by Brokerages

July 26, 2025 | marketbeat.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

July 16, 2025 | zacks.com

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

July 8, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)

June 24, 2025 | theglobeandmail.com

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

June 23, 2025 | globenewswire.com

Larimar Therapeutics to Host Conference Call on Regulatory Updates for Nomlabofusp Clinical Development Program

June 22, 2025 | nasdaq.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia

June 20, 2025 | finance.yahoo.com

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

June 20, 2025 | globenewswire.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock

May 24, 2025 | investing.com

Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential

May 21, 2025 | insidermonkey.com

Why Larimar Therapeutics, Inc.’s (LRMR) Stock Is Down 6.40%

May 6, 2025 | aaii.comA

Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss

May 4, 2025 | tipranks.com

Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development

May 4, 2025 | msn.com

Larimar Therapeutics Reports First Quarter 2025 Financial Results

April 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, LRMR, and CGC Company Descriptions

ALX Oncology NASDAQ:ALXO

$0.52 -0.05 (-8.70%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$0.53 +0.01 (+1.91%)

As of 08/1/2025 05:31 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$2.51 -0.22 (-8.06%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$2.54 +0.03 (+1.24%)

As of 08/1/2025 06:30 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Canopy Growth NASDAQ:CGC

$1.05 +0.02 (+1.94%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.06 +0.01 (+0.95%)

As of 08/1/2025 07:59 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Larimar Therapeutics NASDAQ:LRMR

$3.44 -0.02 (-0.58%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.49 +0.05 (+1.45%)

As of 08/1/2025 07:38 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time